<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410005</url>
  </required_header>
  <id_info>
    <org_study_id>14-00039</org_study_id>
    <secondary_id>NPRP No: 4-1392-3-345</secondary_id>
    <secondary_id>14-00039</secondary_id>
    <nct_id>NCT02410005</nct_id>
  </id_info>
  <brief_title>Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)</brief_title>
  <acronym>IDEAL</acronym>
  <official_title>Kidney Disease in Type 2 Diabetes Mellitus: Biomarker Discovery and Novel Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Cornell Medical College in Qatar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Cornell Medical College in Qatar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center open-label randomized controlled trial designed to evaluate the&#xD;
      efficacy of calcitriol plus losartan therapy in subjects with type II diabetes and&#xD;
      macroalbuminuria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to test the efficacy and safety of a combined regimen of calcitriol&#xD;
      and losartan in subjects with type II diabetes (T2DM) with macroalbuminuria. Should the&#xD;
      investigators study confirm the hypothesis that the proposed novel regimen is superior to the&#xD;
      current practice of renin-angiotensin-aldosterone system blockade, the study would&#xD;
      significantly advance the care of subjects with type II diabetes and kidney disease in Qatar&#xD;
      and worldwide. In this regard it is worth noting that the prevalence of end stage renal&#xD;
      disease in Qatar is 202 subjects per million population. This would translate into fewer&#xD;
      subjects requiring dialysis or transplantation, an enormous benefit to individuals and&#xD;
      society.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Logistic challenges&#xD;
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 7, 2015</completion_date>
  <primary_completion_date type="Actual">September 7, 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24h urine 24hr urine albuminuria</measure>
    <time_frame>12 month</time_frame>
    <description>24h urine albuminuria (log transformed) from baseline to 12 months post-randomization in the losartan plus calcitriol group compared to the losartan alone group.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Urine mRNA/miRNA expression</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Urine Albumin-to-Creatinine Ratio (UACR)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure (BP)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estimated glomuerula filtration rate (eGFR)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Losartan alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan and Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <arm_group_label>Losartan and Calcitriol</arm_group_label>
    <other_name>1,25-dihydroxycholecalciferol</other_name>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan alone</arm_group_label>
    <arm_group_label>Losartan and Calcitriol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of T2DM requiring treatment with at least one oral hypoglycemic medication&#xD;
             or insulin&#xD;
&#xD;
          2. Macroalbuminuria as defined as the presence of a UACR greater than 300 mg/gm&#xD;
             creatinine (30 mg/mmol creatinine) on two occasions in the last six months&#xD;
&#xD;
          3. Estimated eGFR of 30 to 90 mL/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive Pregnancy Test or planning pregnancy in the subsequent 18months (if female)&#xD;
&#xD;
          2. Serum Calcium &gt; 2.45 mmol/L (9.8 mg/dL)&#xD;
&#xD;
          3. Serum Phosphorus &gt; 1.78 mmol/L (5.5 mg/dL)&#xD;
&#xD;
          4. Serum Potassium &gt; 5.5 mmol/L (5 mEq/L)&#xD;
&#xD;
          5. Parathyroid hormone &lt; 20 pg/mL or &gt; 500 pg/mL&#xD;
&#xD;
          6. Hemoglobin A1C &gt; 12%&#xD;
&#xD;
          7. 25-OH Vit D &gt; 50 ng/mL&#xD;
&#xD;
          8. Poorly controlled hypertension defined as systolic blood pressure &gt;= 180 mm Hg or&#xD;
             diastolic blood pressure &gt;= 110 mm Hg&#xD;
&#xD;
          9. History of kidney stones&#xD;
&#xD;
         10. History of severe disease like chronic liver disease&#xD;
&#xD;
         11. Active malignancy&#xD;
&#xD;
         12. Active granulomatous diseases like turburculosis and sarcoidosis&#xD;
&#xD;
         13. Recent diagnosis of acute renal failure within 3 months of screening visit&#xD;
&#xD;
         14. Likelihood of renal replacement therapy within 1 year&#xD;
&#xD;
         15. History of parathyroidectomy&#xD;
&#xD;
         16. Currently taking calcitriol or 1,25-dihydroxyvitamin D analog&#xD;
&#xD;
         17. Currently taking calcitonin, bisphosphonates, cinacalcet, teriparatide,&#xD;
             glucocorticoids or other drugs that may affect calcium or bone metabolism (subjects&#xD;
             may be taking calcium containing phosphate binder or other phosphate binder. Subjects&#xD;
             may also be taking stable dose of estrogen/progestin)&#xD;
&#xD;
         18. History of osteoporosis or other bone disorder requiring calcitriol therapy&#xD;
&#xD;
         19. History of allergic reaction to calcitriol, paracalcitol, hectoral, or other&#xD;
             1,25-dihydroxyvitamin D analogs&#xD;
&#xD;
         20. History of allergic reaction to losartan or any other angiotensin receptor blocker&#xD;
             therapy&#xD;
&#xD;
         21. Evidence of drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis August, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College in Qatar</name>
      <address>
        <city>Doha</city>
        <zip>24144</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Qatar</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

